Beneficial microbes最新文献

{"title":"Effects of food matrix on the prebiotic efficacy of inulin-type fructans: a randomised trial","authors":"P.P.J. Jackson, A. Wijeyesekera, S. Theis, J. Van Harsselaar, R.A. Rastall","doi":"10.1163/18762891-20220120","DOIUrl":"https://doi.org/10.1163/18762891-20220120","url":null,"abstract":"Abstract Recently there is much debate in the scientific community over the impact of the food matrix on prebiotic efficacy of inulin-type fructans. Previous studies suggest that prebiotic selectivity of inulin-type fructans towards bifidobacteria is unaffected by the food matrix. Due to differences in study design, definitive conclusions cannot be drawn from these findings with any degree of certainty. In this randomised trial, we aimed to determine the effects that different food matrices had on the prebiotic efficacy of inulin-type fructans following a standardised 10-day, 4-arm, parallel, randomised protocol with inulin either in pure form or incorporated into shortbread biscuits, milk chocolate or a rice drink. Similar increases in Bifidobacterium counts were documented across all four interventions using both fluorescence in situ hybridisation (pure inulin: 0.63; shortbread: 0.59; milk chocolate: 0.65 and rice drink: 0.71 (log 10 cells/g wet faeces) and 16S rRNA sequencing quantitative microbiome profiling data (pure inulin: 1.21 × 10 9 ; shortbread: 1.47 × 10 9 ; milk chocolate: 8.59 × 10 8 and rice drink: 1.04 × 10 9 (cells/g wet faeces) (all ). From these results, we can confirm that irrespective of the food matrix, the selectivity of inulin-type fructans towards Bifidobacterium is unaffected, yet the compositional make-up of the food matrix may have implications regarding wider changes in the microbiota.","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136349974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome.","authors":"E Ermolenko, S Sitkin, T Vakhitov, O Solovyeva, A Karaseva, A Morozova, M Kotyleva, I Shumikhina, N Lavrenova, E Demyanova, A Dmitriev, A Suvorov","doi":"10.3920/BM2022.0053","DOIUrl":"10.3920/BM2022.0053","url":null,"abstract":"<p><p>Intestinal microbiota correction in the therapy of irritable bowel syndrome (IBS) is an important medical problem. We conducted a laboratory and pilot clinical trial to investigate the effect of autoprobiotic bacteria, indigenous bifidobacteria and enterococci isolated from faeces and grown on artificial media to use as personified food additives in IBS treatment. Convincing evidence of the clinical efficacy of autoprobiotic was demonstrated by the disappearance of dyspeptic symptoms. The microbiome of patients with IBS was compared to a group of healthy volunteers and changes in the microbiome after autoprobiotic use were detected by quantitative polymerase chain reaction and 16S rRNA metagenome analysis. The possibility of reducing opportunistic microorganisms in the treatment of IBS with autoprobiotics has been convincingly proven. The quantitative content of enterococci in the intestinal microbiota was higher in IBS patients than in healthy volunteers and increased after therapy. An increase in the relative abundance of genera <i>Coprococcus, Blautia</i> and a decrease in the relative abundance of <i>Paraprevotella</i> spp. were found at the end of therapy. A metabolome study which was performed by gas chromatography and mass spectrometry demonstrated an increase in the content of oxalic acid, a decrease of dodecanoate, lauric acid, and other metabolome components after taking autoprobiotics. Some of these parameters correlated with the relative abundances of <i>Paraprevotella</i> spp., <i>Enterococcus</i> spp., and <i>Coprococcus</i> spp. representative of the microbiome. Apparently, they reflected the peculiarities of metabolic compensation and changes in the microbiota. Therefore, the use of autoprobiotics for treatment of IBS may lead to a stable positive clinical effect, associated with compensatory changes in the intestinal microbiota, and accompanied by corresponding changes in metabolic processes in the organism.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"119-130"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9347763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heat-killed <i>Lactobacillus helveticus</i> improves mood states: a randomised, double-blind, placebo-controlled study.","authors":"N Mutoh, I Kakiuchi, A Hiraku, N Iwabuchi, K Kiyosawa, K Igarashi, M Tanaka, M Nakamura, M Miyasaka","doi":"10.3920/BM2022.0048","DOIUrl":"10.3920/BM2022.0048","url":null,"abstract":"<p><p>We investigated the effects of heat-killed <i>Lactobacillus helveticus</i> MCC1848 on daily mood states in healthy young adults. Participants (n=58) were randomised to receive heat-killed <i>L. helveticus</i> MCC1848 powder or placebo powder for 4 weeks. During the study period, adverse events were recorded in the participant diary. Mood states were assessed before and 2 and 4 weeks after initiation of the intervention. The primary outcomes were the shortened version of the Profile of Mood States 2 (POMS 2) scores. Secondary outcomes included other mood state (State-Trait Anxiety Inventory (STAI); visual analogue scale (VAS)), quality of life (acute form of the SF-36v2), sleep (Athens Insomnia Scale (AIS)) and fatigue (Chalder Fatigue Scale (CFS)) scores. Four weeks of heat-killed <i>L. helveticus</i> MCC1848 intake, compared to placebo, significantly improved the shortened version of the POMS 2 'friendliness' and the VAS 'relaxed' scores, which are two indicators of positive mood states. On the other hand, heat-killed <i>L. helveticus</i> MCC1848 intake had no significant effects on negative mood state items (e.g. anger, nervousness, confusion) assessed by the shortened version of the POMS 2, STAI and VAS. AIS and CFS scores also showed no significant differences. No adverse effects were observed with 4 weeks of heat-killed <i>L. helveticus</i> MCC1848 intake. These results suggest that daily consumption of heat-killed <i>L. helveticus</i> MCC1848 is safe and has the potential to improve positive mood states. <b>UMIN Clinical Trial Registry</b>: UMIN000043697.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"109-118"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9685789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of <i>Lactobacillus crispatus</i>-containing oral and vaginal probiotics on vaginal health: a randomised double-blind placebo controlled clinical trial.","authors":"R Mändar,&nbsp;G Sõerunurk,&nbsp;J Štšepetova,&nbsp;I Smidt,&nbsp;T Rööp,&nbsp;S Kõljalg,&nbsp;M Saare,&nbsp;K Ausmees,&nbsp;D D Le,&nbsp;M Jaagura,&nbsp;S Piiskop,&nbsp;H Tamm,&nbsp;A Salumets","doi":"10.3920/BM2022.0091","DOIUrl":"https://doi.org/10.3920/BM2022.0091","url":null,"abstract":"<p><p>Health of reproductive tract is tightly associated with balance of microbial communities in this area. Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) represent common disturbances of vaginal communities. Vaginal discharge due to BV or VVC is a very frequent reason for visiting gynaecologist. We aimed to evaluate the impact of the novel evidence-based probiotics on BV and VVC patients. The study group included 89 BV and 93 VVC patients (aged 18-50 years) who were recruited into randomised double-blind placebo-controlled two-arm parallel trial. The patients of each diagnosis group received oral or vaginal probiotic capsules, or placebo capsules during 3 months. A probiotic capsule contained two (DSM32717 and DSM32720, in case of BV) or three (DSM32720, DSM32718 and DSM32716, in case of VVC) <i>Lactobacillus crispatus</i> strains. Vaginal, intestinal and general health was monitored weekly by questionnaire. Blood analyses were done in the beginning and at the end of trial. Vaginal samples were collected monthly, microscopic and molecular analyses were performed. The study revealed that both oral and vaginal capsules reduced the signs and symptoms in BV patients. Remarkable improvement was noted in Nugent score, amount and smell of discharge, but also in itching/irritation. Consumption of vaginal probiotics significantly increased the lactobacilli counts in their vagina while mean proportion of some BV-related bacteria decreased. In VVC patients, both oral and vaginal capsules lowered the combined score of two most important symptoms, amount of discharge and itching/irritation. In conclusion, the novel formulations of evidence-based well-focused probiotic <i>L. crispatus</i> strains are effective against BV and VVC being suitable for both vaginal and oral administration. Clinical trial registration: ISRCTN34840624, BioMed Central.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"143-152"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9335008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of <i>Bacillus clausii</i> CSI08, <i>Bacillus megaterium</i> MIT411 and a <i>Bacillus</i> cocktail on gastrointestinal health: a randomised, double-blind, placebo-controlled pilot study.","authors":"K Rea,&nbsp;J Colom,&nbsp;E A Simon,&nbsp;E Khokhlova,&nbsp;S Mazhar,&nbsp;M Barrena,&nbsp;M Enrique,&nbsp;P Martorell,&nbsp;B Alvarez Perez,&nbsp;M Tortajada,&nbsp;C Phipps,&nbsp;J Deaton","doi":"10.3920/BM2022.0117","DOIUrl":"https://doi.org/10.3920/BM2022.0117","url":null,"abstract":"<p><p>In the present study, the safety, tolerance and impact of 1×10⁹ cfu <i>Bacillus clausii</i> CSI08, 1×10⁹ cfu <i>Bacillus megaterium</i> MIT411 and a probiotic cocktail containing <i>Bacillus subtilis</i> DE111^®, <i>Bacillus megaterium</i> MIT411, <i>Bacillus coagulans</i> CGI314, and <i>Bacillus clausii</i> CSI08 with a total count of 2.0×10⁹ cfu administered daily were assessed as compared with a maltodextrin containing placebo control. A total of 98 study participants received daily doses for 45 days, followed by a washout period of 2 weeks. A questionnaire to capture the incidence and duration of upper respiratory tract, urinary tract and/or gastrointestinal complaints and a diary to capture stool regularity and consistency was kept daily to record compliance throughout the 45 days. Faecal and blood samples were collected for microbiological and haematological analysis at the start and end of the treatment period. The probiotic cocktail significantly decreased the incidence of loose stools throughout the entire study. The recorded respiratory, urinary and gastrointestinal symptoms, defecation frequency and other stool consistency were not influenced. No clinically relevant changes in blood parameters, such as liver and kidney function and no serious adverse events appeared during and after administration. There were no changes in symptoms including sadness, irritability, energy, appetite, tension, stress, sleep, cardiovascular events, aches and pains, and dizziness as determined by a mood questionnaire administered to participants at baseline and at the end of the treatment period. Similarly, the measured inflammatory cytokines, antioxidant levels, cholesterol, triglycerides, free amino acids or minerals remained unaffected. There were no negative changes in alpha or beta diversity of the microbiota with any of the treatment groups. These promising data suggest that these treatments were safe and well tolerated, and further work with larger cohorts are justified to determine the efficacy of these potential probiotics in select demographic groups. Trial registration number with clinicaltrials.gov at NCT04758845.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"165-182"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9685791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Agave</i> fructans enhance the effects of fermented milk products on obesity biomarkers: a randomised trial.","authors":"M Vega-Cárdenas,&nbsp;F Martínez-Gutierrez,&nbsp;E E Lara-Ramírez,&nbsp;E Reynaga-Hernandez,&nbsp;L Yañez-Estrada,&nbsp;S Ratering,&nbsp;S Schnell,&nbsp;C I Godínez-Hernández,&nbsp;J M Vargas-Morales,&nbsp;D P Portales-Pérez","doi":"10.3920/BM2022.0078","DOIUrl":"https://doi.org/10.3920/BM2022.0078","url":null,"abstract":"<p><p>Dysbiosis has been implicated in childhood obesity. Oral intake of fermented milk containing <i>Lacticaseibacillus casei</i> strain Shirota preserves gut microbiota (GM) diversity in children and adults. This study was a double-blind trial involving 37 overweight or obese children aged 6-10 years. Children were followed over a 6-week intervention period in which they received different fermented milk products containing <i>L. casei</i> Shirota: 10 in the first group received just <i>L. casei</i> Shirota; 13 received <i>L. casei</i> Shirota with 3 g/day of inulin (<i>L. casei</i>+inulin); and 14 received <i>L. casei</i> Shirota with 3 g/day of fructans from <i>Agave salmiana</i> (<i>L. casei</i>+fructans). Principal component analysis showed the relationship between microbial abundance, GM metabolites, and other obesity-related markers. Supplementation with probiotics and synbiotics improved the HDL-cholesterol levels of overweight and obese children, although no changes in body composition were detected. We observed an increase in butyrate or propionate concentrations in the <i>L. casei</i>+fructans group compared to the end of the intervention (<i>P</i><0.03). A diminished level of ANGPTL4 within the <i>L. casei</i>+fructans group (<i>P</i>=0.04) was also found, but no differences when lipopolysaccharide-binding protein was evaluated. The FFAR2+ cell frequency decreased between baseline and at the end of 6-week intervention in <i>L. casei</i>+inulin (<i>P</i>=0.02) and <i>L. casei</i>+fructans groups (<i>P</i>=0.04). In contrast, the percentage of CD14+FFAR3+ frequency increased in the same groups (<i>P</i>=0.04). The <i>L. casei</i> Shirota with inulin or fructans modulates GM, which improves the lipid profile and changes at a molecular level, such as expression of FFAR3 and FFAR2, ANGPTL4, propionate, and butyrate. It, therefore, could be considered an interesting therapeutic possibility for treating childhood overweight and obesity. The study was registered at ClinicalTrials.gov (ID: NCT05423015).</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"153-164"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9335009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Covariates of vaginal microbiota and pro-inflammatory cytokine levels in women of reproductive age.","authors":"J Novak, C S T Ferreira, M A Golim, M G Silva, C Marconi","doi":"10.3920/BM2022.0060","DOIUrl":"10.3920/BM2022.0060","url":null,"abstract":"<p><p>This study aimed to assess the correlation between covariates of the vaginal microbiota and local levels of proinflammatory cytokines in women of reproductive age presenting four molecularly defined bacterial community-state types (CSTs). We enrolled 133 non-pregnant women who attended primary care health clinics for routine Pap-testing. Molecular profiling of vaginal microbiota was performed by V3-V4 16S rRNA sequencing. The covariates of vaginal microbiota included were: vaginal pH, total bacterial cell count, diversity (Shannon index), -richness and dominant taxa abundances. Levels of interleukin (IL)-1β, IL-6, IL-8, and tumour necrosis factor (TNF-α) were measured by enzyme-linked immunosorbent assays in supernatants of cervicovaginal fluids. Nonparametric Kruskal-Wallis test was used to compare microbiota covariates and cytokines among different CSTs. Spearman's tests were performed to assess correlations across the measured parameters. A total of 96 (72.2%) participants had CSTs dominated by <i>Lactobacillus</i> spp. (<i>Lactobacillus crispatus</i> CST I, n=38; <i>Lactobacillus gasseri</i> CST II, n=20; and <i>Lactobacillus iners</i> CST III, n=38). A total of 37 (27.8%) presented the <i>Lactobacillus-depleted</i> CST IV. Total bacterial count was higher in CST II (1.29E+05, 3.40E+04-6.69E+05) compared to other <i>Lactobacillus-dominated</i> CSTs (<i>p</i>=0.0003). The highest values of microbiota diversity (1.85; 0.23-2.68) and richness (27.0; 5.0-37.0) were observed in CST IV (<i>P</i><0.0001). Lower levels of IL-1β were observed in CST I (5.4; 0.0-3,256) when compared to CST III (51.7; 0.0-2,616) and to CST IV (56.2; 0.0-3,407) (<i>P</i>=0.008). Levels of IL-6 were higher in CST II (4.13; 0-131.4) than in CST IV (0.0-58.27) (<i>P</i>=0.02). Correlation tests showed an overall distinct profile of CST II when compared to other <i>Lactobacillusdominated</i> CSTs, particularly regarding the correlation between total bacterial load and cytokines (r>0.39). In conclusion, this study provides evidence of a single pro-inflammatory signature of <i>L. gasseri</i>-dominated microbiota in response to bacterial load. Further studies evaluating a broader range of inflammation markers are warranted.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"131-142"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9700396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotic adjuvant treatment in combination with scaling and root planing in chronic periodontitis: a systematic review and meta-analysis.","authors":"J Li, G Zhao, H M Zhang, F F Zhu","doi":"10.3920/BM2022.0056","DOIUrl":"10.3920/BM2022.0056","url":null,"abstract":"<p><p>This systematic review and meta-analysis assessed the impact of probiotic supplementation on treating chronic periodontal (CP) disease based on clinical and microbiological findings. Four databases were searched: Medline, Embase, Cochrane Library, and the Web of Science databases. The references to relevant studies were also manually searched. Analyses were conducted using the Review Manager 5.2 software, while the quality of randomised controlled trials was assessed with the Cochrane Risk of Bias tool. In total, 19 studies were included in the meta-analysis. Pooled results revealed that the adjuvant use of probiotics in the treatment of patients with periodontal disease was largely associated with good clinical efficacy. Resulting in statistically significant improvements in plaque index (<i>P</i><0.05), periodontal probing depth (<i>P</i><0.05), clinical attachment level (<i>P</i><0.05), gingival index (<i>P</i><0.05), bleeding on probing (<i>P</i><0.05), deep probing depth (<i>P</i><0.05), and levels of subgingival microbes (<i>P</i><0.05) following probiotic supplementation. In summary, the results of this meta-analysis suggest that the administration of probiotics together with scaling and root planing can somewhat improve CP patient clinical outcomes and reduce levels of periodontal pathogens. However, more comprehensive experiments are needed to standardise probiotics and maximise their adjuvant therapy.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 2","pages":"95-108"},"PeriodicalIF":5.4,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9335010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic, metabolomic, and functional characterisation of beneficial properties of <i>Pediococcus pentosaceus</i> ST58, isolated from human oral cavity.","authors":"L Favaro,&nbsp;S Campanaro,&nbsp;J I I Fugaban,&nbsp;L Treu,&nbsp;E S Jung,&nbsp;L d'Ovidio,&nbsp;D P de Oliveira,&nbsp;M-T Liong,&nbsp;I V Ivanova,&nbsp;S D Todorov","doi":"10.3920/BM2022.0067","DOIUrl":"https://doi.org/10.3920/BM2022.0067","url":null,"abstract":"<p><p>Bacteriocins produced by lactic acid bacteria are proteinaceous antibacterial metabolites that normally exhibit bactericidal or bacteriostatic activity against genetically closely related bacteria. In this work, the bacteriocinogenic potential of <i>Pediococcus pentosaceus</i> strain ST58, isolated from oral cavity of a healthy volunteer was evaluated. To better understand the biological role of this strain, its technological and safety traits were deeply investigated through a combined approach considering physiological, metabolomic and genomic properties. Three out of 14 colonies generating inhibition zones were confirmed to be bacteriocin producers and, according to repPCR and RAPD-PCR, differentiation assays, and 16S rRNA sequencing it was confirmed to be replicates of the same strain, identified as <i>P. pentosaceus</i>, named ST58. Based on multiple isolation of the same strain (<i>P. pentosaceus</i> ST58) over the 26 weeks in screening process for the potential bacteriocinogenic strains from the oral cavity of the same volunteer, strain ST58 can be considered a persistent component of oral cavity microbiota. Genomic analysis of <i>P. pentosaceus</i> ST58 revealed the presence of operons encoding for bacteriocins pediocin PA-1 and penocin A. The produced bacteriocin(s) inhibited the growth of <i>Listeria monocytogenes, Enterococcus</i> spp. and some <i>Lactobacillus</i> spp. used to determine the activity spectrum. The highest levels of production (6400 AU/ml) were recorded against <i>L. monocytogenes</i> strains after 24 h of incubation and the antimicrobial activity was inhibited after treatment of the cell-free supernatants with proteolytic enzymes. Noteworthy, <i>P. pentosaceus</i> ST58 also presented antifungal activity and key metabolites potentially involved in these properties were identified. Overall, this strain can be of great biotechnological interest towards the development of effective bio-preservation cultures as well as potential health promoting microbes.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 1","pages":"57-72"},"PeriodicalIF":5.4,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9119479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, tolerability, and acceptability of <i>Lactobacillus crispatus</i> CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth.","authors":"E Bayar, D A MacIntyre, L Sykes, K Mountain, T P Parks, P P Lee, P R Bennett","doi":"10.3920/BM2022.0084","DOIUrl":"10.3920/BM2022.0084","url":null,"abstract":"<p><p>The vaginal microbiota is a determinant for the risk of preterm birth (PTB). Dominance of the vaginal niche by <i>Lactobacillus crispatus</i> associates with term delivery. This is the first observational clinical study of live vaginal biotherapeutics (<i>Lactobacillus crispatus</i> CTV-05 (LACTIN-V)) in pregnant women at high-risk of PTB. The primary aim was to explore safety, tolerability and acceptability of LACTIN-V in pregnancy. Women were offered a course of LACTIN-V at 14 weeks gestation for five consecutive days followed by weekly administration for six weeks. Participants were followed up at 15, 18-, 20-, 28- and 36-weeks' gestation and at delivery for assessment of adverse events, compliance and tolerability. Participants completed a questionnaire to gauge experience and acceptability. In total, 73 women were recruited, of whom eight withdrew, leaving a final cohort size of 61. Self-reported compliance to the course was high (56/60, 93%). Solicited adverse events were reported in 13 women (19%) including changes in vaginal discharge, odour, colour or consistency of urine, itching and vaginal bleeding. One unsolicited adverse event was reported as haematuria at 38 weeks gestation, but was judged to be unrelated to LACTIN-V. No serious adverse events occurred. One mild adverse event led to study withdrawal. Thirty-one women completed an experience and acceptability questionnaire. Women found LACTIN-V easy and comfortable to use and the majority (30/31, 97%) would use LACTIN-V in future pregnancies. Eight women (8/31, 26%) found the schedule of use difficult to remember. The rate of PTB <34 weeks in this cohort was 3.3% compared to 7% in a historical cohort of 2,190 women at similar background PTB risk. With satisfactory uptake and good compliance, we demonstrate that LACTIN-V is safe and accepted in pregnancy, with high tolerability. Further studies are needed to assess colonisation of <i>Lactobacillus crispatus</i> CTV-05 and clinical efficacy.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 1","pages":"45-56"},"PeriodicalIF":5.4,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9119481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}